http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2085994-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c9446a65422eaca792040fe2b817fb5 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 |
filingDate | 1992-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5323b531ef6d9ab8bba2043d3334208d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6504d89d16eae8da4909f504f165164d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86acec88a1d9cddd782b522b3faf49a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6424809223bb1d9330fc2eaab11dc1f |
publicationDate | 1992-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2085994-A1 |
titleOfInvention | 1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives |
abstract | ABSTRACT The present invention relates to a novel 1-.beta.-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivative represented by the following formula (I), whose concentration in blood as XVAU can be kept high for many hours when it is administered orally. The present invention also relates to an antiviral agent comprising as an active ingredient the compound of the present invention. Further, the present invention relates to a method for treating viral diseases which comprises administering to a patient with a viral disease a safe and effective amount of the compound of the present invention. (I) wherein X represents a halogen; and R1, R2 and R3, which may be the same or different, each represent a hydrogen atom, a lower alkyl group or an aralkyl group, provided that R1, R2 and R3 are not hydrogen at the same time. |
priorityDate | 1991-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.